Sialyl-Tn-positive tumour-derived extracellular vesicles impair dendritic cell function via horizontal transfer of glycans

Cancer cells release tiny bubbles called extracellular vesicles (EVs) that carry a specific sugar called Sialyl-Tn (STn). These bubbles act like "Trojan horses." They enter immune cells—specifically dendritic cells—and deliver both the sugar and the biological machinery required to manufacture more of it. This process effectively shuts down the immune response. This allows the tumor to grow undetected.

The blind spot in immune evasion

In the fight against triple-negative breast cancer (TNBC), the battleground is often the tumor microenvironment (TME). This is the complex ecosystem of cells and signaling molecules surrounding a tumor. A critical player here is the dendritic cell (DC). DCs are professional antigen-presenting cells (cells that show pieces of pathogens to the immune system).

Think of DCs as the intelligence officers of the immune system. They survey the body for abnormal cells. They then "present" pieces of those cells (antigens) to T cells to trigger an attack. Most modern immunotherapies rely heavily on these DCs. They must prime a robust anti-tumor response to work.

However, many patients do not respond to these treatments. Tumors use various signals to hide from the immune system. One such signal involves aberrant glycosylation (the irregular attachment of sugar chains to proteins). Researchers wanted to know if these sugars were active weapons. They aimed to see if they could reprogram the immune system via the cargo of extracellular vesicles.

A two-pronged hijacking mechanism

The authors of this study sought to determine if STn-positive EVs could actively manipulate DC function. They engineered MDA-MB-231 TNBC cells to overexpress the enzyme ST6GalNAc-I. This enzyme produces the STn glycan. This created a controlled model of "STn+ EVs" to compare against standard "Mock" control vesicles.

The mechanism of suppression operates through a dual-action delivery system, as seen in .

First, the vesicles act as direct messengers. The STn-decorated proteins on the EV surface bind to inhibitory Siglec receptors on the dendritic cells. Much like a key fitting into a lock to disable a security system, this binding prevents the DC from activating.

Second, the vesicles act as biological freight. The authors report that these EVs carry the ST6GalNAc-I enzyme itself. Upon being taken up by the dendritic cells, the EVs deliver this enzymatic machinery. This allows the dendritic cell to begin synthesizing its own STn antigens. The immune cell becomes a carrier of the very signal that suppresses it.

Measuring the immunosuppressive payload

The researchers measured several key metrics to quantify this "hijacking." Regarding vesicle production, the authors report that STn-overexpressing cells produced a significantly higher concentration of particles. They found approximately $300 \pm 9.5 \times 10^{10}$ particles/mL. This is much higher than the $180 \pm 8.3 \times 10^{10}$ particles/mL found in the control. The vesicles were also larger, with a mean diameter of $125 \pm 7.4$ nm compared to $85 \pm 9.8$ nm .

The functional impact on the immune system was profound. The paper finds that DCs exposed to STn+ EVs showed a near-complete loss of essential maturation markers. These include CCR7 and HLA-DR .

This lack of maturation caused a failure in the T cell response.

Specifically, the authors report that STn+ EVs led to a 55% reduction in CD4 T cell proliferation. They also saw a 70% reduction in CD8 T cell proliferation. Meanwhile, the expansion of regulatory T cells (Tregs, which suppress immune responses) increased by 45% .

Crucially, the authors demonstrated that this effect is specifically tied to the sugar. When they used an enzyme called sialidase to strip the terminal sialic acids from the STn EVs, the suppressive effects were reversed. The DCs regained their ability to mature and activate T cells .

Limits of the in vitro model

While the evidence is compelling, the study has notable boundaries. The researchers conducted these experiments using an in vitro model. This means they worked with isolated cell lines in a controlled laboratory environment. The authors acknowledge that these cell cultures cannot fully replicate a living tumor microenvironment. A real tumor has complex fluid flow and varying oxygen levels.

Furthermore, while the study proves that the ST6GalNAc-I enzyme and STn antigen are transferred to the DCs, the internal logistics are unknown. The precise way vesicles are swallowed and how cargo is released remains unmapped. Finally, the study does not yet distinguish between two causes. It is unclear if suppression comes from direct sugar-receptor contact or from the long-term effect of the delivered enzyme.

The verdict: A new target for precision oncology

Is this ready for the clinic? Not yet, but the direction is clear. The study provides a mechanistic basis for why certain TNBC patients exhibit poor survival.

If the findings hold in human tissue, the implications are twofold. First, measuring STn levels in circulating extracellular vesicles could serve as a "liquid biopsy." This could help predict how well a patient might respond to immunotherapy. Second, the fact that sialidase treatment reverses the suppression suggests a new therapeutic avenue. Scientists could use enzymes to "strip" the protective sugar coating off tumor vesicles. This would re-arm the patient's own dendritic cells to attack the cancer.

Figures from the paper